News

Editor's Top Picks

Your one-stop resource for personal news and tips.

Join our newsletter to get the latest news directly to your inbox.

More form News

Noble Corporation: Not Enough Upside (NYSE:NE)

We have so far published notes with a Buy rating on Seadrill (SDRL) and Valaris

LVMH becomes late addition to running order of Paris Olympic sponsors

Receive free Olympic Games updatesWe’ll send you a myFT Daily Digest email rounding up the

Tidewater: Warrant Expiry – Potential Arbitrage Opportunities (NYSE:TDW)

Image: "Deepwater Horizon" offshore oil rig and Tidewater supply vessel. Review of Share Price Action

Israeli parliament approves first part of judicial overhaul

Receive free Israel updatesWe’ll send you a myFT Daily Digest email rounding up the latest

Cogeco Communications: An Undervalued Infrastructure Stock Offering A Growing Yield

Cogeco Communications (TSX:CCA:CA) is a cable company providing internet, phone and video services in North

US bank deposit data questioned amid tensions over SVB bailout

Receive free US banks updatesWe’ll send you a myFT Daily Digest email rounding up the

Koninklijke KPN N.V. (KKPNF) Q2 2023 Earnings Call Transcript

Koninklijke KPN N.V. (OTCPK:KKPNF) Q2 2023 Earnings Call Transcript July 24, 2023 7:00 AM ET

Credit Suisse fined $388mn over Archegos collapse

Receive free Archegos Capital Management updatesWe’ll send you a myFT Daily Digest email rounding up

Munich Re Shines, Fraport Stagnates, K+S Drops: Reviewing My German Stocks After A Year

Back in May 2022, I decided to invest in three German stocks: reinsurer Munich Re

Twitter/X: maverick rebrand leaves Musk with a cross to bear

Receive free Twitter Inc updatesWe’ll send you a myFT Daily Digest email rounding up the

Dirt Cheap – Why I’m Buying Valero Ahead Of Earnings (NYSE:VLO)

Introduction It's time to talk about one of the most volatile dividend growth stocks in

Antony Blinken & Gina Raimondo: To shape the future of AI, we must act quickly

Receive free Artificial intelligence updatesWe’ll send you a myFT Daily Digest email rounding up the

CureVac’s CVGBM Trial: Promising Results Progress Pipeline (NASDAQ:CVAC)

CureVac's (NASDAQ:CVAC) unique dual-variant approach, employing both unmodified and modified mRNA, positions them at the

China politburo vows support for economy but gives few details

Receive free Chinese economy updatesWe’ll send you a myFT Daily Digest email rounding up the

Small Cap Alpha, Commodity Danger, ADES With Courage & Conviction Investing

Listen below or on the go via Apple Podcasts or Spotify. Courage & Conviction Investing